CompletedPhase 3NCT01247207
Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)
Studying Duchenne muscular dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PTC Therapeutics
- Principal Investigator
- Vinay Penematsa, MDPTC Therapeutics, Inc.
- Intervention
- Ataluren(drug)
- Enrollment
- 270 enrolled
- Eligibility
- MALE
- Timeline
- 2010 – 2026
Study locations (30)
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- UCLA, Los Angeles, California, United States
- Stanford University, Palo Alto, California, United States
- University of California-Davis, Sacramento, California, United States
- University of CA, San Francisco-Benioff Children's Hospital, San Francisco, California, United States
- Children's Hospital Colorado - Center for Cancer and Blood Disorders, Aurora, Colorado, United States
- Child Neurology Center of NW Florida NW, Gulf Breeze, Florida, United States
- Rare Disease Research, LLC, Atlanta, Georgia, United States
- Rush Univ Medical Center, Chicago, Illinois, United States
- University of Iowa Children's Hospital, Iowa City, Iowa, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Children's Hospital of Boston/Harvard Medical School, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01247207 on ClinicalTrials.govOther trials for Duchenne muscular dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07332013Urinary Titin Biomarker in DMDChildren's Hospital of Philadelphia
- RECRUITINGNCT07092540The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular DystrophyUniversity of Rochester
- ENROLLING BY INVITATIONNANCT06887491The Effect of Dual-tasking Program on Cognitive and Physical Functions and Independence in Activities of Daily Living in Children With Duchenne Muscular Dystrophy: A Single-blind Randomized Controlled TrialLokman Hekim University
- ACTIVE NOT RECRUITINGPHASE1NCT07347548A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male ParticipantsGrünenthal GmbH
- ENROLLING BY INVITATIONPHASE2NCT07209332Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular DystrophyWave Life Sciences Ltd.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07282652A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular DystrophyPeking Union Medical College Hospital
- RECRUITINGPHASE2NCT07287189Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsSatellos Bioscience, Inc.
- ENROLLING BY INVITATIONNCT07435116Duchenne Muscular Dystrophy and the Viscoelastic Properties of Upper Limb MusclesSanko University